Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

42%
Prodromal Participants
Enrollment Goal: 100

9%
Genetic Cohort Participants
Enrollmen Goal: 600

8%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment Goal: 400

100%
Control Participants
Enrollment Goal: 200

100%
Subjects with SWEDD
Enrollment: 64

Last Update: October 14, 2014

 

More about study cohorts >

Welcome

Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

New Publication on SPECT Imaging and Executive Function

A new study using PPMI data was published in the journal Movement Disorders exploring the relationship between cognitive impairment and dopaminergic deficits in unmedicated Parkinson’s patients.


PPMI Protocol Updated

PPMI was designed to be adaptable to changing needs, targets, and opportunities in research. In reflection of this, PPMI recently updated its study protocol to include new and revised procedures and assessments. View a summary of the latest changes.


Daytime Sleepiness and Fatigue Associated with Cognitive Impairment

A recent publication in the journal Parkinsonism and Related Disorders used PPMI data to find that more severe daytime sleepiness and fatigue are associated with greater cognitive impairment. The study’s researchers used PPMI data as well as data from two other studies in order to examine this relationship across the different stages of Parkinson’s.


First Longitudinal Findings: Psychiatric Symptoms More Common in Untreated PD Patients than Controls

The first longitudinal findings from PPMI have been published. Researchers from the University of Pennsylvania affiliated with PPMI published in the journal Neurology that depression, anxiety and fatigue are more common in newly diagnosed Parkinson’s disease patients compared to the general population.


Core Focus: the Genetics Coordination Core

The PPMI study cores are responsible for a wide range of study needs including analyzing, storing, and performing quality control measures on the study data and specimens, providing supplies, guidance, and support to study sites, and performance and study management. In this core spotlight, Genetics Coordination Core Principal Investigator Tatiana Foroud, PhD and her team explain their role in PPMI.


Learn More